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ABSTRACT 
Malnutrition is a costly problem for health care systems internationally. Malnourished individuals 
require longer hospital stays and more intensive nursing care than adequately nourished individuals 
and have been estimated to cost an additional £7.3 billion in health care expenditures in the United 
Kingdom alone. However, treatments for malnutrition have rarely been considered from an 
economic perspective.  The aim of this systematic review was to identify the cost effectiveness of 
using protein and energy supplementation, as a widely used intervention to treat adults with and at 
risk of malnutrition.  Papers were identified that included economic evaluations of protein or energy 
supplementation for the treatment or prevention of malnutrition in adults. While the variety of 
outcome measures reported for cost effectiveness studies made synthesis of results challenging, 
cost benefit studies indicated that the savings for the health system could be substantial due to 
reduced lengths of hospital stay and less intensive use of health services after discharge.  In 
summary the available economic evidence indicates that protein and energy supplementation in 
treatment or prevention of malnutrition provides an opportunity to improve patient wellbeing and 
lower health system costs. 
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INTRODUCTION 
Malnutrition is a costly problem for health care systems internationally.1 In Australia, the 
additional cost of malnutrition to the Victorian public health system has been recently 
estimated as $10.7 million per year with the authors noting that this is likely to greatly 
underestimate the true costs.2 In the UK the annual cost to the health system has been 
estimated at more than £7.3 billion, mostly due to increased costs of hospital and long-term 
care.1 It has been identified that up to 55% of hospital patients at any one point in time are 
malnourished.3-5 In addition, up to 50% of residential care and 30% of community living 
elderly have been found to be malnourished.3,6-8  The consequences of malnutrition upon an 
individual’s health are severe and impact negatively upon health care expenditure through 
increases in the frequency and duration of hospital episodes, and increased intensity of 
health and community service utilization following discharge from hospital.9-13   
Containment of increasing health care expenditures is a global phenomenon and 
increasingly economic evaluation is being utilised as a tool for demonstrating the efficiency 
or value for money of health care expenditures. In a world of increasing resource constraints 
for health care expenditures, demonstrating not only the clinical effectiveness but also the 
cost effectiveness of nutrition interventions for the treatment of malnutrition in adult 
populations in hospital, residential and community settings is becoming a key evidential 
requirement for health care decision-makers. Whilst previous reviews9 have highlighted the 
clinical effectiveness of interventions for the treatment of malnutrition, no review to date 
has systematically sought to identify and report upon the quality of, the economic 
evaluation methods used in published studies of treatments for malnutrition. 
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Previous studies have identified the most common treatments for malnutrition are 
strategies to increase energy and protein intake via the normal oral route, such as enriched 
diets, high energy and protein snacks and oral nutrition supplements.14 Therefore, our 
primary aim was to undertake a systematic review to identify economic evaluation studies of 
protein and energy supplementation for the treatment of people with or at risk of 
malnutrition.  A secondary aim was to provide an overview of the quality of the economic 
evidence available on this topic. 
METHODS 
Defining and categorising economic evaluation 
Economic evaluation may be defined as the comparative analysis of alternative courses of 
action in terms of both their costs and consequences.15 Therefore the fundamental 
requirements of any economic evaluation are to identify, measure, value and compare the 
costs and consequences of the alternatives being considered. There are five generally 
accepted forms of economic evaluation for health care interventions which are described in 
Table 1.16,17 Briefly they are cost-minimisation analysis, cost-benefit analysis, cost-
consequence analysis, cost-effectiveness analysis, and cost-utility analysis.  It is appropriate 
to conduct a cost minimisation analysis of a health care intervention only where there is 
sound evidence (e.g. through the findings of a well conducted randomised controlled trial) to 
indicate that there is no difference in outcomes for both effectiveness and safety between 
the intervention under consideration and the most appropriate alternative intervention.18 
Within cost benefit analysis both costs and benefits are measured and valued in monetary 
terms to determine the net benefit of the new intervention e.g. as a consequence of  
reductions in future health care costs due to decreases in morbidity and/or mortality.  On 
4 
 
the other hand cost-consequence, cost-effectiveness, and cost-utility analysis all compare 
the benefits of interventions through a focus upon changes in clinical and/or patient focused 
outcomes.  A cost-effectiveness analysis (CEA) involves a direct comparison of the costs 
associated with an intervention with a single measure of effectiveness which is usually 
clinically or bi-medically focused.  This allows the calculation of an incremental cost 
effectiveness ratio (ICER) where the additional costs of the treatment are divided by 
additional benefits of providing the treatment e.g. cost per one unit improvement in blood 
cholesterol levels.  Cost consequence analysis is a form of economic evaluation where the 
incremental costs associated with the new intervention are calculated and a series of 
outcomes or consequences are presented but the costs and outcomes are not presented 
together in the form of a ratio. Cost-utility analysis (CUA) is a particular form of CEA which 
warrants special consideration as it is explicitly the preferred method of economic 
evaluation for many health regulatory bodies in Australia (Pharmaceutical Benefits Advisory 
Committee (PBAC)), United Kingdom (National Institute for Health and Clinical Excellence) 
and many other bodies around the world.18-19  Within CUA benefits are measured and valued 
using ‘utility’, where this reflects preference for a particular health state.20  Once measured, 
the utility of a particular health state or series of health states can be combined with the 
quantity or number of life years a person spends in the health state  to give an indicator of 
the Quality Adjusted Life Years (QALY) attributable to an intervention and ultimately a ICER 
of cost per QALY gained.  There are many ways of measuring utility, but a commonly utilised 
method is through the use of a multi-attribute utility instrument (MAUI).21 A MAUI is a 
validated instrument that provides both a framework to describe health states for valuation, 
and can have a developed algorithm to convert those health states into utility weights or 
values which indicate the preference of the population for those health states.  Generally a 
value of one is assigned for a health state representing perfect health, zero for death, with 
other health states falling on a continuum between these two points.  Negative values 
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indicating a health state perceived as worse than death can be possible.  It is these utility 
values which can be combined with the length of time a person spends in a health state to 
determine QALY.  There are a number of MAUI which have been developed in different 
populations, but some of the most common include EQ-5D, Short Form 6D, Health Utilities 
Indexes, and Quality of Well-Being.15  The scales have different advantages and 
disadvantages depending on the attributes of health included in the scale, and the number 
of levels of ability or impairment for each of the attributes which need to be appropriately 
matched to the population being studied and the expected impact of the intervention.21 
However, the advantage the MAUI share in measuring utility is they cover not only the 
expected effects of the intervention on mobility or pain for example, but also the flow on 
effects to independence, and ability to carry out your usual role within society.  MAUI 
therefore have the opportunity to track the effects of interventions more broadly than 
through traditional clinical outcomes, and allow comparisons of interventions targeting 
different outcomes, for example providing medications for asthma compared to controlling 
hyperlipidaemia.  This flexibility in application and interpretation has led to CUA using MAUIs 
being the most preferred method of economic evaluation.   Many regulatory bodies for 
health have a threshold (either explicit or not) for the cost per QALY ICER below which 
interventions are likely to be considered cost effective, such as the National Institute for 
Health and Clinical Excellence which recommends cost per QALY ICER’s below £20,000.19   
Search Strategy 
A search strategy was developed largely replicating that published by Milne et al.9 in their 
review of protein and energy supplementation for treatment of malnutrition in older adults, 
but with additional search terms to identify studies including economic evaluation (see 
Appendix 1 in supplementary information).  While the review published by Milne et al.9 
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originally dealt with only older adults (average age 65 years and above), due to the paucity 
of economic evidence we widened our search strategy to include all adults (18 years and 
above) thereby facilitating a broader analysis of the quality of the economic literature. 
Inclusion criteria are as follows.  We included hospitalised, residential aged care and 
community dwelling populations. We focused specifically upon economic evaluation studies 
reported either as stand-alone papers or as components of papers which also included a 
broader focus upon clinical effectiveness.  Interventions of interest were those aiming to 
increase the energy and protein levels of individuals via oral administration.  Interventions 
which included a mix of interventions such as nutrition screening and assessment, dietary 
advice, and feeding assistance in addition to protein and energy supplementation were 
included.  Types of studies included were any comparative study, including randomised 
controlled trials, and non-randomised controlled trials. Studies employing economic 
modelling methods were also included.  Exclusion criteria included trials purely based on 
patients in critical care or recovering from cancer treatment as these patients typically have 
highly specialised nutritional needs.  In addition trials of specialised nutrition components 
such as specific amino acids or immunomodulatory components were excluded due to 
differences in the effect and cost data for these products. Relevant comparators included 
‘usual practice’ (i.e. ad hoc dietary care or a different nutritional supplement with different 
energy and protein content) or a ‘placebo’ (such as a low energy drink).   
Databases searched included Cochrane register of Controlled Trials (until December 2012), 
Medline (from 1946 until December 2012), Scopus (until December 2012), Web of 
Knowledge (until December 2012), CINAHL (until December 2012) and Australasian Medical 
Index (until December 2012). 
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In addition, any reviews of the topic that were identified through the above methods were 
checked for additional studies that had not been previously identified.  Reference lists of 
identified articles or reviews of protein and energy supplementation or evaluation of 
nutrition therapy were also checked for additional references.  
 Data Collection and Analysis 
Two reviewers independently identified studies from the search results for further analysis 
by scanning the title, abstract, and key words of the studies for evidence that they compared 
a protein and energy supplemented diet with no intervention, a placebo, or an alternative 
supplement and involved adult participants.  If there was any doubt about the eligibility of 
the article, it was also retrieved for further investigation.  
All information was extracted independently by the two reviewers.  All differences in 
extraction were clarified with a third reviewer by going back to the original article.  
Information extracted included: study design, participants, intervention, sample size, follow 
up period, results, sensitivity analysis (which measures the variability around the base-case  
results), and discounting of future costs and benefits (where applicable).15  The quality of the 
economic evaluations in the articles was assessed using the 35 point checklist developed by 
Drummond and colleagues for quality submission of economic evaluations to journals.15  
These criteria assess the quality of the economic evaluation in terms of study design, data 
collection, analysis and interpretation of results, and allow assessment of economic 
evaluations based on single trial data and combinations of data into economic models.  
Similarly to the previous review, we did not exclude studies based on the nutritional status 
of the participants, but identified studies were categorised into one of two groups according 
to whether they had targeted malnourished patients only (according to the criteria within 
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the paper) or did not specify the nutritional status of their participants for entry to the study 
for ease of interpretation and reporting of results. 
RESULTS 
Description of Studies 
2,750 titles were identified through the search (Figure 1).  Of those titles, the vast majority 
could be excluded via reading the titles or the abstract (2,632 out of the 2,750), as their 
focus was not health care but agricultural practices or animal health or manufacturing of 
food, or did not include an intervention to increase dietary energy or protein.  A total of 118 
papers had the full text of the title accessed and of those a further 100 were excluded due to 
lack of an intervention to increase energy and protein intake via the normal oral route (e.g. 
included parental nutrition or naso-gastric, naso-enteric, or percutaneous endoscopic 
gastrostomy (PEG) feeding (n=15), did not include economic outcomes (n=32), did not 
include a dietary intervention to increase energy or protein (n=47) or were testing 
supplementation of immunomodulatory components within a protein and energy 
supplement (n=6). Two papers were protocols for studies not yet published and were 
therefore excluded.  This left 16 papers focused upon economic evaluation which were 
included in the review.   
Results of studies where participants were defined as malnourished 
Six studies targeted malnourished patients using a variety of identification methods (e.g. 
Subjective Global Assessment, Mini Nutritional Assessment, BMI, history of unplanned 
weight loss), listed in Table 2.  Of those studies three were cost utility studies,22,23,24  with the 
remaining studies being cost benefit analyses25,26 and a cost consequence analysis 
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respectively.27  The cost utility studies22,23,24 and the cost consequence analysis27 were based 
on the results of randomised controlled trials both with sample sizes of 100 participants or 
more while the cost benefit analyses25,26 were based on modelled data.  All of the studies 
utilized oral nutritional supplements (ONS) as their intervention, although Norman et al.23 
also provided dietary counselling to their intervention and control groups.  The participants 
were from different clinical groups with two studies focusing on patients with 
gastrointestinal disease,23,26 two with older adults admitted to hospital,22,27 one with older 
adults in residential care facilities,24 and one in community dwelling older adults.25 The 
studies also differed in the costs they included in their analysis.  Norman et al.23 only 
included the incremental cost of the intervention in their analysis, excluding any wider effect 
on the health system, while most other studies took a wider view point including costs of 
medical treatment  and social care in the community.22,25,27  There was a great variety in 
outcomes measured as listed in Table 2. The cost utility analysis by Norman et al.23 found 
that providing 3 months of ONS to malnourished patients with benign gastrointestinal 
disease was associated with between €9497-12099 per quality-adjusted life year (QALY) 
gained. Although in Australia no explicit guideline for determining the cost effectiveness of 
new healthcare technologies has been provided, the Pharmaceutical Advisory Committee 
appears to consider interventions with cost per QALY below $50,000 as cost effective, and 
this intervention is well within this threshold indicating relatively high cost effectiveness.28   
Neelemat et al.22 neared the cost-effectiveness threshold in their CUA providing ONS to 
older people admitted to hospital as well as routine Vitamin D and Calcium supplementation 
and telephone support from a Dietitian upon discharge. The results indicated a cost per 
QALY gain of €26962 for the intervention group compared to the controls. Cost benefit 
studies conducted by Freijer et al. in the Netherlands indicated cost savings of over €200 per 
patient in abdominal surgery patients receiving 2 cartons of ONS per day during their 
hospitalisation through a reduced length of stay,26 and reported total budget savings of over 
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€12 million for the provision of ONS for treatment of malnutrition in community dwelling 
older people.25 Pham et al.24 found provision of ONS for the treatment of pressure ulcers in 
malnourished patients of residential care facilities was not cost effective in isolation, but 
argued that nutrition may play a wider role in supporting other prevention strategies beyond 
the scope of the economic model developed for their analysis. The remaining study was 
conducted in a community dwelling sample of older people over a 6 to 12 month follow up 
period and failed to demonstrate any cost savings for an 8 week intervention in a population 
of elderly and already malnourished subjects.27  In summary therefore although the available 
economic evidence is scant, the studies which have been undertaken to date do 
demonstrate the potential for  protein and energy supplementation in patients identified as 
malnourished to provide cost savings to the health system in addition to improved health 
outcomes for patients.  
Results of studies where nutritional status not specified 
Table 3 presents the results of studies including an intervention to improve nutritional status 
in a group of participants where their nutritional status was not specified.29-38 Although 
relatively more studies were identified in this category, the studies were very diverse in 
terms of setting, interventions, and outcomes measured, making any direct comparisons 
across studies very difficult.  In terms of study design, a range of designs were employed 
including randomised designs,29-31,35 a number of non or quasi-randomised 
designs32,33,36,37and modelled studies.34,38  Although sample size varied from less than 100 to 
over 2000, half of the studies included between 100 and 300 participants.  Of the identified 
studies only one utilized a cost-utility approach.29 This study assessed a multidisciplinary 
intervention including exercise and smoking cessation counselling in addition to ONS in 
community dwelling adults with chronic obstructive pulmonary disease and was found to be 
near the cost effectiveness threshold at AUD$39,438 per QALY gained (Table 3).  Four of the 
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studies utilized a cost-effectiveness analysis and reported upon a diverse range of outcome 
indicators including cost per one day reduction in length of stay, cost per kilocalorie 
consumed, or cost per kg of weight gained.30-33 Findings ranged from cost of US$0.01 per 
kilocalorie additional consumed to cost of €76.10 per one day reduction in length of stay.  
Although Dangour et al.30 found an ICER of US$4.84 per additional meter walked by their 
intervention group in a timed walking test, they only included the costs for the physical 
activity intervention not the nutrition intervention in their estimates, which could lead to an 
underestimate.  All of these included ONS, aiming to provide between 1068kJ and 10g 
protein and to 2500kJ and 28g protein additional per day.  Other interventions utilized 
included mid meal snacks, or fortified foods and five studies included a multifaceted 
intervention (two of which included an exercise or multidisciplinary intervention, and three 
which included routine early screening for nutritional status and issues).  The studies also 
focused on different clinical groups such as patients from residential care homes,31,37 
patients with COPD discharged to the community,29 community dwelling older adults,30 and 
a large number focusing on patients from various hospital wards.32-36,38 Follow up period was 
similarly varied across the studies ranging from the duration of hospital stay to a two year 
period, with the greatest proportion of studies (five out of nine) centred on the period of 
hospitalisation. In addition, the costs included in the analysis varied from the incremental 
costs of providing the intervention only,30-32 compared to wider viewpoints including the 
costs of providing the intervention and medical treatment over the follow up time 
period.29,33-37 One study focused on the changes in hospitalisation costs only. 38  Overall, 
while the heterogeneity of the studies makes synthesis of the outcomes difficult, they have 
generally indicated beneficial outcomes for the patient or health system, at a relatively low 
cost.   
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Quality of Studies 
Overall when assessing the quality of the published studies, according to the widely 
recognised Drummond criteria the quality ranges greatly between studies, (Figure 2).  
Studies were of varying quality, with the number of ‘yes’ responses to the criteria ranging 
from a minimum of three to maximum of 27.  Generally, the studies scored well on question 
1 (“the research question is stated”), 5 (“the alternatives being compared are clearly 
described”), 22 (“time horizon of costs and benefits is stated”), and 32 (“conclusions follow 
from the data reported”).  Questions completed less well included 14 (“productivity changes 
if included are reported separately”), 15 (“the relevance of productivity changes to the study 
question is discussed”), 23 (“the discount rate is stated”), and 24 (“the choice of rate is 
specified”).  
The paper which had the highest number of ‘yes’ responses to the criteria (n=28) was Pham 
et al.,24 a recently published CUA of ONS in Residential Care patients closely followed by 
Norman et al.23 (n=27) a cost utility study of ONS in malnourished patients with benign 
disease. This study found that ONS was cost effective.    In general, it was found that the 
more recently published Cost Utility22,23,29 and Cost Effectiveness studies30-33 were of a higher 
quality than older published studies in terms of their adherence to the Drummond criteria. A 
few studies included only a partial report of healthcare costs such as general practitioner or 
health service visits.27,37,38  However, these studies fail to provide a direct comparison 
between the costs and benefits provided by the interventions, and they therefore fail to take 
into consideration the value for money of the interventions from an economic perspective.39 
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DISCUSSION 
In a comprehensive review of the published literature, sixteen papers were identified which 
included analysis of providing protein and energy supplementation for prevention or 
treatment of malnutrition from an economic view point.  Of these, only four studies22,23,24,29 
utilised cost-utility analysis, which is currently recommended as the preferred method of 
economic evaluation for  new health care interventions by the Pharmaceutical Benefits 
Advisory Committee and Medical Services Advisory Committee in Australia, and the National 
Institute for Health and Clinical Excellence in the UK as well as many other regulatory bodies 
around the world.18-19   
Two of the cost-utility studies identified by the review concluded that the interventions 
under consideration (ONS for 3 months in patients with benign gastrointestinal disease who 
were also malnourished and ONS for 2 years in adults with Chronic obstructive pulmonary 
disease) were cost effective.23,29  In both studies, the incremental cost per QALY ratios were 
below threshold values for determining cost effectiveness.28  In another CUA, Neelemaat et 
al. 201222 neared the cost-effectiveness threshold for their intervention of ONS in 
malnourished hospitalised older adults, while Pham et al.24 did not show cost effectiveness 
in prevention of pressure ulcers for in malnourished older people living in residential care 
facilities. 
The studies identified in this review indicated an incremental cost of between -€392.00 to 
478.20 (AUD$488.67- $596.12) for health outcomes such as a reduction in one day length of 
stay, additional metre walked, additional calories ingested, or per kg of weight gained.30-38.  
However, while these indicators appear broadly favourable, it is difficult to synthesise these 
outcomes due to their heterogeneous nature.40  The utilization of the QALY, a generic 
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measure of health outcome, for application within  cost-utility analysis can be  helpful in this 
regard in demonstrating the ‘value for money’ of nutrition therapy in a world of competition 
for scarce health budget resources.40  The paucity of economic evidence has also been 
proposed as the main reason for the failure for uptake of national and international 
evidence based guidelines in the clinical setting.40  Within this context, the lack of economic 
evaluations of protein and energy supplementation for malnutrition treatment coupled with 
the lack of utility-based outcomes for facilitating comparison across interventions and 
disease areas for decision-making is therefore a serious concern.   
In addition, there were a small number of published studies targeted at the economic 
benefits of protein and energy supplementation to treat malnutrition in the older adult.  
However, this target group has received more attention  recently, with three cost utility 
studies have been published recently within the last two years targeting the effectiveness of 
providing ONS to malnourished older people.22,24,25  Of three cost effectiveness studies 
identified that targeted older participants, one failed to include the cost of the nutrition 
therapy itself  in their estimation of cost effectiveness (which involved a physical function 
measure).30  However, it is encouraging to see that there have been two randomised 
controlled trial protocols published since 2008 which include economic evaluation in their 
proposed evaluation of research into energy and protein supplementation as a treatment for 
or to prevent malnutrition.41-42  These two studies are all focused on older adults and the 
study protocols all include consideration of costs of the intervention and associated health 
care utilisation (including costs of the nutrition intervention, specialist staff, hospital costs, 
community services, and medications) as well as non-medical costs (such as absenteeism 
and unpaid help) and health outcomes as such as QALYs, and functional status.   
Many identified studies have a short follow up time of one year or less.   This presents a 
challenge for clinicians aiming to demonstrate the benefits of nutrition support, as the short 
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follow up time may not be long enough to allow the benefits to become apparent.  When 
one study in community living elderly over a 6 to 12 month follow up period did not show 
cost savings in the intervention group compared to the control group, the authors 
hypothesised that their 8 week intervention was not sufficient to show improvement in their 
elderly and already malnourished population.27 Also, the results of economic evaluations 
should be reported as an incremental cost effectiveness ratio (ICER) wherever possible. An 
ICER is important as it provides the decision-maker with the opportunity to determine the 
potential additional cost of a new health care intervention in order to achieve a given 
outcome. The use of a generic measure of health outcome such as the QALY in this context 
has the added advantage of facilitating comparisons of value for money across the health 
care system for example comparing investment in nutrition interventions for malnutrition in 
older people versus pharmacological treatments for dementia  
In conclusion, to date few economic evaluations of protein and energy supplementation for 
treatment or prevention of malnutrition have been published and the quality of published 
studies is highly variable. However, the available economic evidence suggests that providing 
ONS of between 1068kJ and 10g protein up to 4200kJ and 23g protein is associated with 
positive economic benefits in both patients with malnutrition and in studies where 
nutritional status was not specified, and over short follow up times.  Use of protein and 
energy supplementation in those with or at risk of malnutrition presents an opportunity for 
health services to reduce hospitalisation costs for a relatively small additional investment.  In 
the absence of comprehensive economic evidence relating to its cost effectiveness, nutrition 
therapy is in danger of falling by the wayside in this new era of competitive health care 
funding.  Future research should focus on the inclusion of high quality comprehensive 
economic evaluations alongside studies of clinical effectiveness to demonstrate the cost 
effectiveness of nutrition interventions for the treatment of malnutrition.  
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Table 1. Types of Economic Evaluation 
Type of 
Evaluation 
Abbreviation Aim Variables Outcomes Example 
Cost-utility 
analysis 
CUA Compares the costs associated with an 
intervention with a measure of utility which 
combines the life years gained by an 
intervention with a measure of the  quality 
of those life years  
Resource costs 
Measure of utility (e.g. 
Quality Adjusted Life 
Year (QALY)) 
Ratio of cost per QALY 
gained 
Cost per QALY for a fish oil 
intervention which reduces joint pain 
in patients with arthritis. 
Cost-
effectiveness 
analysis 
CEA Compares the costs associated with an 
intervention with a measure of clinical 
effectiveness 
Resource costs 
Measure of clinical 
effectiveness 
Cost per unit of clinical 
effectiveness 
Cost of a unit reduction in blood 
cholesterol levels for a nutrition 
education intervention 
Cost-
consequence 
analysis 
CCA Compares the costs associated with an 
intervention with the consequences neither 
without combining these inputs nor without 
indicating the relative importance of the 
consequences. 
Resource costs 
Consequences 
List of costs 
List of possible outcomes 
Up to the reader to make 
judgements about the 
benefits and drawbacks 
of the intervention 
Cost of providing a nutrition education 
intervention, and a reported reduction 
in blood cholesterol levels in an 
intervention group, but without 
combining these outcomes into a ratio.   
Cost –benefit 
analysis 
CBA Compares the benefits of the intervention in 
monetary terms with the costs of the 
intervention 
Resource Costs 
Benefits of the 
intervention in money 
Net benefit of the 
intervention expressed in 
monetary terms 
Commonly used for when a new 
treatment might involve an initial 
expenditure for treatment, but overall 
results in savings over time through 
reduce healthcare utilization. 
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Cost-
minimisation 
analysis 
CMA Determine the least costly intervention 
where outcomes for two interventions are 
assumed to be equal 
Resource costs Difference in resource 
costs between two 
interventions 
Measure the costs of providing 
hospital in the home program when 
the outcomes in morbidity, function, 
quality of life have been shown to be 
the same for as for inpatient care. 
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Table 2: Design and cost outcomes of included studies when participants defined as malnourished 
Citation Design Intervention Population n 
Subjects 
Follow Up Method Sensitivity 
Analysis  
Discounting Unit Cost per unit Cost 
Intervention  
Cost 
Comparison 
Neelemaat 
et al. 
201222 
RCT ONS 
(2520kJ and 
24g protein) 
and 
malnutrition 
treatment 
protocol 
Hospitalised 
older adults 
(Malnourished 
according to 
BMI or weight 
loss) 
210 3 months CUA Yes N/A Additional 
QALY 
€26962  
$US33703 
€9129 (1227)1,2 
$US11411 
(1534) 
€8684 (1361)1,2 
$US10855 
(1701) 
Norman et 
al. 201123 
RCT ONS 3/12 
(2505kJ and 
23g protein) 
Benign GI 
disease 
(Malnourished 
according to 
SGA) 
120 
I=60 
C=54 
3 months CUA Yes N/A Additional 
QALY 
€9497-12099  
$US11904-
15164 
 
€561 (514-
609)3,4   
$US703 (644-
763) 
€22 (0-73)3,4 
$US28 (0-92) 
Pham et 
al. 201124 
Model ONS (1 
carton per 
day, 
8.4kJ/mL 
formula ) 
Residential 
Care 
(Malnourished 
according to 
weight loss) 
N/A 3.8 years CUA Yes Yes Additional 
QALY 
$CAN7824747 
$US74306502 
- - 
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Freijer et 
al. 201225 
Model ONS (2 
cartons per 
day, NFS) 
Community 
dwelling older 
people 
720223 1 year CBA Yes N/A Total budget 
savings 
€12986000 
$US16232500 
€2626570005 
$US328321250 
€2756430005 
$US344553750 
Freijer et 
al. 201026 
Model ONS (2 
cartons per 
day, NFS) 
Abdominal 
surgery  
N/A Per 
admission 
CBA Yes N/A Mean cost of 
hospitalisation 
-€252  
$US316 
- - 
Edington 
et al. 
200427 
RCT ONS from 
hospital 
(2500 – 
4200kJ) 
Recently 
hospitalised 
older adults 
(Malnourished 
according to 
BMI or weight 
loss)  
100 
I=51 
C=49 
6 months CCA  No N/A - - £2989 (4418)2,6 
$US4752 
(7024) 
£2146 (2238)2,6 
$US3412 
(3558) 
Abbreviations: BMI=Body Mass Index, C=Control, GI=Gastrointestinal, I=Intervention, N/A=Not applicable, NFS= Not further specified, ONS=Oral nutritional supplements, 
QALY=Quality adjusted life year, RCT=Randomised controlled trial, SGA=Subjective global assessment, 95%CI=95% Confidence intervals 
1a Standard Error 
2 Costs included for providing medical treatment and social services only 
3 Costs included for providing intervention only 
4 95% CI 
5 Costs included for medical treatment and social services related to treatment of DRM 
6 Standard Deviations 
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Table 3: Design and cost outcomes of included studies where nutritional status not specified 
Citation Design Intervention Population n Subjects Follow Up  Method Sensitivity 
Analysis  
Discount Unit  Cost per 
Unit 
Cost 
Intervention 
 
Cost 
Comparison 
 
Hoogendoorn 
et al. 201029 
RCT ONS 4/12 
(2351kJ and 
28g protein) 
plus multi-
disciplinary 
intervention 
COPD 199 
I=102 
C=97 
 
2 years CUA Yes  No Additional 
QALY 
€32425  
$US40400 
€135651 
$US16901 
€108141 
$US13474 
Dangour et 
al. 201130 
Randomised 
factorial trial 
ONS (1068kJ 
and 10g 
protein) and/or 
physical 
activity  
Community-
dwelling 
older adults 
1669 
ONS = 414, 
ONS+PA=45
2 PA=403 
Cd=400 
2 years CEA Yes Yes Additional 
meter walked 
in 6 minute 
walking test 
$US4.842 Nutrition 
intervention 
$US913 
 
- 
Simmons et 
al.  
201031 
RCT Snacks or 
ONS (NFS) 
Residential 
Care  
63 
ONS=18 
Snacks=24 
C=19 
6 weeks CEA  Yes N/A Additional 
kCal 
consumed 
$US0.01 ONS $US2.13 
(0.37)3,4 
- 
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Kruizenga et 
al. 200532 
Historical 
controlled trial 
Malnutrition 
treatment 
protocol 
including 
high energy 
and protein 
meals (2500kJ 
and 12g 
protein 
additional) 
 
Mixed ward 
patients 
588 
I=297  
(HEHP =98) 
Cd=291 
 
Per 
admission 
CEA Yes N/A Mean cost per 
1 days 
reduction in 
LOS (96%CI) 
€35  
(-1239-
109) 
$US44  
(-1544-
136) 
€37  
(15-58)3,5 
$US46  
(19-73) 
- 
Rypkema et 
al. 2003 33 
Quasi-
randomised 
controlled trial 
Malnutrition 
protocol 
including 
treatment with 
high energy 
diet or ONS 
(NFS) 
Geriatric 
ward 
patients  
298 
I=140 
C = 158 
Per 
admission 
CEA Yes N/A Kg gained -€392 
-$US489 
€75166 
$US9366 
€79086 
$US9854 
Russell 
200734 
Model ONS (NFS) Surgical 
patients 
N/A Per 
admission 
CBA N/A N/A Mean 
difference in  
cost of 
hospitalisation 
intervention 
vs control 
-₤849 
-$US1340 
 
- - 
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Smedley et 
al. 200435 
 
RCT ONS (6.3kJ 
and 0.05g 
protein per ml 
drink ad 
libitum) before 
and after 
surgery (SS 
group) vs ONS 
before (SC 
group) vs ONS 
after (CS 
group) vs 
control (CC 
group)  
 
Surgical 
patients 
152 
CC=44 
SS=32 
CS=35 
SC=41 
Up to 96 
days 
CBA Yes N/A Mean 
difference in 
cost of 
hospitalisation 
intervention 
vs control 
-₤300 
-$US473 
SS ₤2289 
(2034-2717)4,6 
$US3612  
(3209-4287) 
 
₤2618  
(2272-
3181)4,6 
$US4131 
(3585-5019) 
Lawson et al. 
200336 
Prospective 
controlled trial 
ONS (2500kJ 
and 20g 
protein) 
Emergency 
and elective 
orthopaedic 
surgery 
181 
I=84 
C=97 
Per 
admission 
CBA No N/A Mean 
difference in 
cost of 
hospitalisation 
intervention 
vs control 
-₤16 
-$US25 
 
₤20696 
$US3264 
₤21996 
$US3470 
Lorefält et al. 
201137 
Non-
randomised 
controlled trial 
Malnutrition 
protocol 
including high 
energy high 
protein meal 
Residential 
Care  
109 
I=42 
C=37 
1 year CCA  No N/A - - €10056 
$US1253 
€9216 
$US1148 
30 
 
Abbreviations: C=Control, COPD=Chronic obstructive pulmonary disease, GI=Gastrointestinal, HEHP=High energy high protein diet, I=Intervention, LOS=Length of stay, 
N/A=Not applicable, NFS=Not further specified, ONS=Oral nutritional supplements, PA=Physical activity, QALY=Quality adjusted life year, 
1 Costs included for providing intervention plus medical treatment and loss of income for participant 
2 Costs included for providing physical activity intervention only 
3 Costs included for providing intervention only 
4 Standard deviations 
5 95% Confidence intervals 
6 Costs included for providing intervention and medical treatment
options (NFS) 
for 3 months 
Tucker and 
Miguel 
199638 
Model ONS  (NFS) Hospital 
patients 
2485 Per 
admission 
CCA  N/A N/A Mean 
difference in 
cost of 
hospitalisation 
per year 
intervention 
vs control 
-$US8294 - - 
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Legend for Figure 1. Flow diagram of study selection process 
Legend for Figure 2. Results of the quality analysis of the study designs. 
Bars indicate the number of studies for which the quality criteria was met (black bar), not met (white bar), or not 
applicable for this study (grey bar).  Quality criteria taken from the 35 item checklist by Drummond et al.14  Quality 
criteria divided into items referring to study design (A), data collection (B), and analysis and interpretation of the 
results (C).  Criteria questions are as follows: Q1, the research question is stated; Q2, the economic importance 
of the research is stated; Q3, the viewpoint(s) of the analysis are clearly stated and justified; Q4, the rationale for 
choosing the alternative programmes or interventions compared is stated; Q5, the alternatives being compared 
are clearly described; Q6, the form of economic evaluation used is stated; Q7, the choice of form of economic 
evaluation is justified in relation to the questions addressed; Q8, the source(s) of effectiveness estimates used 
are stated; Q9, details of the design and results of the effectiveness study are given (if based on a single study); 
Q10, details of the method of synthesis or meta-analysis of estimates are given (if based on an overview of a 
number of effectiveness studies); Q11, the primary outcome measure(s) for the economic evaluation are clearly 
stated; Q12, methods to value health states and other benefits are stated; Q13, details of the subjects from 
whom valuations were obtained are given; Q14, productivity changes (if included) are reported separately; Q15, 
the relevance of productivity changes to the study question is discussed; Q16, quantities of resources are 
reported separately from their unit costs; Q17, methods for the estimation of quantities and unit costs are 
described; Q18, currency and price data are recorded; Q19, details of currency of price adjustments for inflation 
or currency conversion are given; Q20, details of any model used are given; Q21, the choice of model used and 
the key parameters on which it is based are justified; Q22, time horizon of costs and benefits is stated; Q23, the 
discount rate(s) is stated; Q24, the discount rate(s) is justified; Q25, an explanation is given if costs or benefits 
are not discounted; Q26, details of statistical tests and confidence intervals are given for stochastic data; Q27, 
the approach to sensitivity analysis is given; Q28, the choice of variables for sensitivity analysis is justified; Q29, 
the ranges over which the variables are varied are stated; Q30, relevant alternatives are compared; Q31 
incremental analysis is reported; Q32, major outcomes are presented in a disaggregated as well as aggregated 
form; Q33, the answer to the study question is given; Q34, conclusions follow form the data reported; Q35, 
conclusions are accompanied by the appropriate caveats.  
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Figure 1. Flow diagram of study selection process 
Records 
identified 
through database 
searching n=2750 
Excluded on review of the 
title or abstract n=2632 
Not healthcare focus 
Did not include an 
intervention to increase 
dietary energy or protein 
Full-Text article 
retrieved and 
assessed for 
eligibility 
n=118 
Excluded on review of the full-
text article n=102 
Intervention not via normal oral 
route: 15 
No economic outcomes: 32 
No dietary intervention to increase 
energy or protein: 47 
Test immunomodulatory 
components within a protein and 
energy supplement vs protein and 
energy supplement only: 6 
Protocols for Studies: 2 
Studies included in 
qualitative analysis n=16 
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Figure 2. Results of the quality analysis of the study designs
 
